Centrosomes, centrioles and cell division: new targets in experimental breast cancer treatment

Collaborative research from Johns Hopkins Medicine (MD, USA) and the University of Oxford (UK) has discovered a novel method of selectively targeting human breast cancer cells by disrupting the activity and function of centrioles in cell division. The team hope to produce a stable drug inhibitor of the TRIM37 protein that controls this mechanism. The technique, so far tested only in lab-grown and patient-derived cancer cells, exploits cancers with a high level of TRIM37 expression to target two parts of centriolar function in cell division. Centriole function is key for the anaphase of cell division and selective inhibition of the...